The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | PHOENIX: ibrutinib in combination with R-CHOP for DLBCL
Stephen Ansell, MD, PhD, of the Mayo Clinic, Rochester, MI, introduces the Phase III PHOENIX trial (NCT01855750) evaluating whether ibrutinib in combination with R-CHOP improves the clinical outcome of patients with newly diagnosed non-GBC diffuse large B-cell lymphoma. Prof. Ansell speaks at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, revealing the unmet primary endpoint of event-free survival, before discussing the significant benefit of the addition of ibrutinib for the younger and fitter patients.
